<DOC>
	<DOCNO>NCT00264875</DOCNO>
	<brief_summary>To evaluate safety efficacy pregabalin reduce neuropathic pain associate HIV neuropathy</brief_summary>
	<brief_title>Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus ( HIV ) Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Participation precede A0081066 doubleblind trial meet entry criterion trial complete A0081066 study visit 7 Experienced serious adverse event A0081066 trial consider related possibly relate study medication investigator sponsor noncompliant A0081066 trial clinically significant unstable medical condition HIVrelated nonHIV relate include limited , cardiac , pulmonary hepatorenal disease , opinion investigator , would compromise participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>